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The importance of hemodialysis session length relative to
small solute (e.g., urea) clearance has been debated for many
years. Longer session length augments clearance of larger
molecules and may facilitate ultrafiltration; however, the
independent effects of session length on survival and other
outcomes are unknown. In this report, we review two
recently published observational studies examining the
association between hemodialysis session length and
survival. Prospective clinical trials will be required to
resolve the debate.
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In a recent issue of Kidney International, two reports resurrect
the role of hemodialysis session length as one of the key
determinants of survival in patients with end-stage renal
disease. Marshall et al.1 examined the association between
hemodialysis session length and survival in 4193 hemodia-
lysis patients from the Australian and New Zealand dialysis
and transplant registry followed prospectively, starting 12
months after the initiation of dialysis to diminish confound-
ing effects of residual kidney function. After adjusting for
demographic factors and comorbid conditions, relative to
session lengths between 4 and 4.5 h, shorter session lengths
(‘t’o3.5 h) were associated with increased mortality (relative
risks 1.69 and 1.57 without and with adjustment for dialysis
‘dose’ estimated using Kt/Vurea); longer session lengths
(4.5–5 h) were associated with a 20% reduction in mortality.
The authors concluded that the ‘optimal combination for
mortality (survival) appears to be Kt/VX1.3 and a session
length of X4.5 h’. The authors suggest that these results are
not due to confounding because of the consistency of results
using multivariable regression and companion analyses
stratified by body size. Causation cannot be inferred because
of confounding by indication; in other words, clinical factors
may have influenced the likelihood of being prescribed a
shorter or longer session length. For example, lower
interdialytic weight gains might have prompted physicians
to prescribe shorter session lengths (assuming Kt/Vurea target
values were reached). As such, higher mortality rates
associated with session lengthso3.5 h may reflect confound-
ing by malnutrition. Similarly, lower mortality rates asso-
ciated with session lengths X4.5 h may reflect confounding
by improved nutritional status, above and beyond what
might be explained by Quete´let’s (body mass) index,
although statistical adjustments for comorbid conditions
and Quete´let’s index did not eliminate the finding. As the
authors rightly note, further adjustment for laboratory vari-
ables, including serum albumin, creatinine, and phosphorus
would have strengthened the analyses.
Saran et al.2 used data from 422 000 patients enrolled in
the Dialysis Outcomes and Practice Patterns Study to
explore the association of dialysis session length and
mortality. The relative risks of o3.5 and 3.5–4 h session
lengths were 1.34 and 1.19 compared with patients dialyzing
for 44 h. The risk profile was strongest in Japan and weakest
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in the US. A significant interaction between Kt/Vurea and
session length was reported so that longer session length
was deemed ‘even more beneficial’. Marshall et al.1 evaluated,
but did not find, such an interaction. Furthermore, there
were redundant terms in the model and extrapolating
the interaction risk curves shown in Figure 42 backward
from 180 to 150 or 120 min suggests that risk would be
higher at Kt/Vurea of 1.6 than at Kt/Vurea of 1.2, rendering the
finding suspect.
The two studies highlighted the relation between Kt/Vurea
and session length in clinical practice and some of the
differences observed here could be due different unmeasured
clinical practice patterns in different parts of the world.
Treatment times tended to be longest in Australia and New
Zealand and shortest in the US. But the association between
Kt/Vurea and session length was weakest in Australia and New
Zealand and strongest in Japan. The association of session
length with death risk was strongest in Australia, New
Zealand and Japan, and weakest in the US. Indeed, higher Kt/
Vurea, required by local clinical practice guidelines, may only
be achievable in persons of larger body size (‘V’) by extension
of session length.3
Previously published observational studies of dialysis
session length have produced conflicting results. Several
studies suggested no independent effect of session length on
survival, if the urea reduction ratio or Kt/Vurea were
maintained above specified ranges,4–7 although most of these
studies are older and US based. The ranges of session length
in most studies were narrow, and heavily confounded by sex,
body size, and other factors. Utilizing data from 471 000
hemodialysis patients, the Japanese Society for Dialysis
Therapy reported a lower risk of death associated with
increases in session length up to 5.5 h after controlling for Kt/
Vurea.
8 In the same analyses, the risk of death associated with
shorter dialysis sessions decreased with higher dialysis dose,
up to a Kt/Vurea of 1.8.
To date, the National Cooperative Dialysis Study (NCDS)
remains the only randomized-controlled trial evaluating the
effect of dialysis session length on patient outcomes. The
NCDS evaluated 151 patients enrolled in four treatment
arms of a 2 2 factorial design. Patients were randomized
to one of two target session lengths (4.5–5 and 2.5–3.5 h)
and one of two target blood–urea–nitrogen concentrations
(TAC, time-averaged urea concentration) (TACurea 100 and
50 mg/dl). The TACurea achieved were 89 and 52 mg/dl,
respectively. All subjects received hemodialysis three times
per week using cellulose dialyzers and acetate-based dialysate.
A high rate of treatment failure in the high blood–urea–
nitrogen groups led to discontinuation of the balanced
study. The high blood–urea–nitrogen– short time group was
dropped immediately but patients in the other arms
were followed for at least 24 weeks. Compared to the strong
effect of TACurea on morbidity and mortality, session
length was considered to have secondary, more minor
effects.9 However, risk was about 80% higher in the short
time arms of the NCDS compared with the long time arms.
Tests of statistical significance reached only P¼ 0.06,
although the magnitude of the effect was large and the
number of patients enrolled small when the balanced study
was discontinued. It is difficult to conclude from the
NCDS that session length is not meaningful; the authors
presciently stated that the study conclusions should be
interpreted cautiously, given the design and limited power
of NCDS. In retrospect, one might argue that the NCDS’
session length P¼ 0.06 was the most significant (important)
‘nonsignificant’ (statistically) effect in the history of dialysis
research.
Both reports published in this issue of Kidney Inter-
national urged that randomized clinical trials be conducted
to resolve the question of the true effects of session length.
Designing such a trial, isolating the effect of session length
independent of dose would be challenging. Some acceptable
minimum dose would need to be provided to both groups in
order to comply with current practice standards, although
the increase in dose for other uremic solutes might vary to a
much greater degree than for urea. Clearance parameters of
multiple solutes, not simply those to which we are now
wedded, should be measured to allow for quantification of
therapy beyond what is provided by the clock. Ultimately,
understanding that dose and session length might not be
disentangled would have to be acceptable to investigators and
the community alike.
There are compelling reasons why a slow and steady
approach to intermittent dialysis might be superior. Given
that conventional hemodialysis typically sustains life but fails
to restore health in the majority of persons with end-stage
renal disease, prospective re-testing of the tortoise’s strategy
is clearly warranted.
REFERENCES
1. Marshall MR, Byrne BG, Kerr PG, McDonald SP. Associations of hemodialysis
dose and session length with mortality risk in Australian and New Zealand
patients. Kidney Int 2006; 69: 1229–1236.
2. Saran R, Bragg-Greshem JL, Levin NW et al. Longer treatment time and
slower ultrafiltration in hemodialysis: association with reduced mortality in
the DOPPS. Kidney Int 2006; 69: 1222–1228.
3. Chertow GM, Owen WF, Lazarus JM et al. Exploring the J-shaped curve
between URR and mortality. Kidney Int 1999; 56: 1872–1878.
4. Collins AJ, Kjellstrand CM. Shortening of the hemodialysis procedure
and mortality in ‘healthy’ dialysis patients. ASAIO Trans 1990; 36:
M145–M148.
5. Owen Jr WF, Lew NL, Liu Y et al. The urea reduction ratio and serum
albumin concentration as predictors of mortality in patients undergoing
hemodialysis. N Engl J Med 1993; 329: 1001–1006.
6. Held PJ, Port FK, Wolfe RA et al. The dose of hemodialysis and patient
mortality. Kidney Int 1996; 50: 550–556.
7. Capelli JP, Kushner H, Camiscioli T et al. Factors affecting survival of
hemodialysis patients utilizing urea kinetic modeling. A critical appraisal of
shortening dialysis times. Am J Nephrol 1992; 12: 212–223.
8. Shinzato T, Nakai S. Do shorter hemodialyses increase the risk of death? Int
J Artif Organs 1999; 22: 199–201.
9. Lowrie EG, Laird NM, Parker TF, Sargent JA. Effect of the hemodialysis
prescription of patient morbidity: report from the National Cooperative
Dialysis Study. N Engl J Med 1981; 305: 1176–1181.
Kidney International (2006) 70, 24–25 25
GM Chertow et al.: Tortoise and hare on hemodialysis m i n i r e v i e w
